Q4: Adj. PTP +13% vs. ABGSCe and +18% vs. cons. on NII & cost. Adj. EPS in '24e-'25e up 3% on wider higher lending. Reiteriate BUY given its strong ROE, yield and superior C/I-ratios.
Adj. PTP beat of 15% vs. ABGSCe, 20% vs. cons. driven by higher NII, better costs (CI/ of 25.7%) and low LLP. Cons. est. rev. likely +3-5% for 24e, less for 25e; Stock up +3-5%.
Sector trading at '24e-'25e P/Es of 8.5x and 9.1x, with abating NIM, and at '23e P/BV 1.2x with normalised ROE of ~14%, still attractive. Adj. EPS up for '24e, down for '25e; we prefer SVEG & MING.
Q4e: NII growth could take a breather q-o-q, but NIM is still to peak. Estimate revisions driven by new rate path. TP of NOK 126 (122) - BUY reiterated for a fast-growing bank.
Sp1 banks are allowed to establish "new" Sp1 Markets. Gains will be moved from Q1'24e to Q4'23e and add to dividend capacity. Prefer MING and SVEG in Norway on more attractive valuation.
Q3: Adj. PTP +9% vs. ABGSCe and +19% vs. cons. on NIM. Adj EPS up 2%, 10% and 4% on wider NIM (deposits). Reiteriate BUY given its strong ROE and superior C/I ratios.
Adj. PTP beat of 12% vs. ABGSCe, 23% vs. cons. mainly driven by its higher net interest income growth. Cons. est. rev. likely +2-4% '24e-'25e; Stock up +1-3% incl DPS
Q3e: NII growth is likely to abate from a very high level. Estimate revisions driven by wider NIM and lending growth. TP of NOK 117 (116) - BUY reiterated for a fast-growing bank.
Q2: adj. net profit +7% vs. ABGSCe and +9% vs. cons ensus. Positive est. rev. amid beat from NII, costs & loan losses. Strong ROE and superior C/I ratios: BUY.
Q1: adj. net profit -2% vs. ABGSCe and -3% vs. cons. Trading at a P/E of 7.9x in '23e-'24e, 6.5% discount to peers. We reiterate BUY at a TP of NOK 107 (108).
Q1e: expect solid reports, but with a neutral risk/reward. Adj. EPS up (higher interest rates) — expect further cons. uplift. Trading in line with historical average — but record earnings